On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
We have now added a new section called the "Assay History List" to the "At A Gla...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...